Our manufacturing sites
Located across Europe, the US and Asia, our cGMP-compliant facilities have the people and technology to create high-end solutions efficiently and at scale.
Contract manufacturing news
Say Hello to us at DCAT Week
March 7, 2023
We are looking forward to attend the DCAT week, coming up in March at the Lotte New York Palace (Novartis Global Biotech Cooperations Suite #4109).
Join us there, to explore business opportunities and partnerships in contract manufacturing.
February 6, 2023
Global Biotech Corporations, the contract manufacturing hub of Novartis is excited to share that we are expanding our portfolio of services by entering into a collaboration with Navigate BioPharma Services Inc, an independently operating subsidiary within the Novartis Group of Companies, to offer innovative solutions and service offerings in the Cell and Gene space.
Global Biotech Cooperations has already established itself as a trusted partner through its manufacturing capabilities and supply chain footprint and the collaboration with Navigate is a significant step towards scaling up and meeting patient needs. Navigate extensively worked towards the development and launch of the world’s first CAR-T therapy and by joining forces with Global Biotech Cooperation also has the potential to offer development process services in the Cell and Gene area.
This is an exciting time for both organizations and we look forward to providing our unique end-to-end services and products to our customers.
We were excited to kick off the 2023 conference season by exhibiting at the Advanced Therapies Week, 17-20 January 2023 in Miami. You were able to meet our colleagues Carrie Bracco, Lauren Perdue, Stuart Macnab BSc (Hons), GCGI, PhD at booth #633 to learn about the Novartis Global Biotech Cooperation’s capabilities in advanced therapies and how we can support you in moving forward with your projects.
Watch the first edition of our webinar series as we discuss the journey of how Novartis GBTC has evolved into a Global Contract Manufacturing Organization over the last 40 years.
The facility will focus on Lenti and Adenoviral vectors, mainly for the contract manufacturing business. The new plant will be located at our Mengeš site in Slovenia and will become operational in early 2024. With this investment, we are addressing the worldwide growth in cell & gene therapies and increasing demand for capacity, driven by the global cell & gene therapy pipeline.
Basel, August 25, 2022 — Novartis today announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off.
Basel, March 10, 2022 — Novartis has signed an initial agreement with Carisma Therapeutics, a biopharmaceutical pioneer in engineered macrophage-based therapeutics, to manufacture the HER 2 targeted CAR-M cell therapy, which is tested in initial trials for the treatment of solid tumors.
Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding its support of the fill and finish of the Pfizer-BioNTech COVID-19 vaccine. Novartis will use its sterile manufacturing facilities at its Novartis Technical Operations site in Ljubljana, Slovenia, to fill at least 24 million doses in 2022.
We’re Novartis Contract Manufacturing Organization that helps customers around the world produce and manufacture life-changing biotechnological products.